Edwards(EW)

Search documents
Edwards(EW) - 2023 Q2 - Earnings Call Transcript
2023-07-27 00:43
Edwards Lifesciences Corporation (NYSE:EW) Q2 2023 Earnings Conference Call July 26, 2023 5:00 PM ET Company Participants Mark Wilterding - SVP, IR and Treasurer Bernard Zovighian - CEO Scott Ullem - CFO Larry Wood - Group President, TAVR and Surgical Structural Hear Daveen Chopra - Global Leader of TMTT Conference Call Participants Robbie Marcus - JPMorgan Matthew Taylor - Jefferies Vijay Kumar - Evercore ISI Larry Biegelsen - Wells Fargo Travis Steed - Bank of America Josh Jennings - Cowen Chris Pasquale ...
Edwards(EW) - 2023 Q1 - Quarterly Report
2023-04-27 16:00
FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the Quarterly Period Ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-15525 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) (State or other ju ...
Edwards(EW) - 2023 Q1 - Earnings Call Transcript
2023-04-27 00:43
Edwards Lifesciences Corporation (NYSE:EW) Q1 2023 Earnings Conference Call April 26, 2023 5:00 PM ET Company Participants Mark Wilterding - SVP, IR and Treasurer Michael Mussallem - Chairman and CEO Scott Ullem - CFO Bernard Zovighian - President Larry Wood - Group President, TAVR and Surgical Structural Hear Daveen Chopra - Global Leader of TMTT Conference Call Participants Larry Biegelsen - Wells Fargo Robbie Marcus - JPMorgan Vijay Kumar - Evercore Joanne Wuensch - Citibank Travis Steed - Bank of Americ ...
Edwards(EW) - 2022 Q4 - Annual Report
2023-02-12 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File Number 1-15525 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 36-4316614 (St ...
Edwards(EW) - 2022 Q4 - Earnings Call Transcript
2023-02-01 03:05
Edwards Lifesciences Corp (NYSE:EW) Q4 2022 Earnings Conference Call January 31, 2023 5:00 PM ET Company Participants Mark Wilterding - VP, IR Michael Mussallem - Chairman & CEO Scott Ullem - Corporate VP & CFO Bernard Zovighian - Corporate VP, Transcatheter Mitral & Tricuspid Therapies Daveen Chopra - Corporate VP, Surgical Heart Valve Therapies Larry Wood - Corporate VP, Transcatheter Aortic Valve Replacement Conference Call Participants Robert Marcus - JPMorgan Chase & Co. Larry Biegelsen - Wells Fargo V ...
Edwards(EW) - 2022 Q3 - Earnings Call Transcript
2022-10-28 01:45
Edwards Lifesciences Corp (NYSE:EW) Q3 2022 Earnings Conference Call October 27, 2022 5:00 PM ET Company Participants Mark Wilterding - VP, IR Michael Mussallem - Chairman & CEO Scott Ullem - Corporate VP & CFO Bernard Zovighian - Corporate VP, Transcatheter Mitral & Tricuspid Therapies Daveen Chopra - Corporate VP, Surgical Heart Valve Therapies Larry Wood - Corporate VP, Transcatheter Aortic Valve Replacement Conference Call Participants Lawrence Biegelsen - Wells Fargo Securities Robert Marcus - JPMorgan ...
Edwards(EW) - 2022 Q3 - Quarterly Report
2022-10-27 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-15525 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 36-43 ...
Edwards(EW) - 2022 Q2 - Earnings Call Transcript
2022-07-29 00:00
Edwards Lifesciences Corporation (NYSE:EW) Q2 2022 Earnings Conference Call July 28, 2022 5:00 PM ET Company Participants Mark Wilterding - VP, IR and Treasurer Mike Mussallem - Chairman and CEO Scott Ullem - CFO Larry Wood - Global Leader, TAVR Bernard Zovighian - Global Leader, TMTT Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Vijay Kumar - Evercore ISI Joanne Wuensch - Citi Cecilia Furlong - Morgan Stanley Travis Steed - Bank of America Suraj Kalia - Oppenheimer Ed ...
Edwards(EW) - 2022 Q2 - Quarterly Report
2022-07-28 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-15525 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 36-4316614 ...
Edwards(EW) - 2022 Q1 - Quarterly Report
2022-04-27 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-15525 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 36-431661 ...